The alkaptonuria therapeutics market, while niche, is witnessing increased attention due to growing awareness and advancements in potential treatments for this rare genetic disorder. This report ...
Nitisinone reduced HGA levels and improved symptoms in patients with alkaptonuria. The Food and Drug Administration (FDA) has approved Harliku ™ (nitisinone) for the reduction of urine homogentisic ...
Alkaptonuria is a rare, autosomal recessive metabolic disorder arising from the deficiency of the enzyme homogentisate 1,2-dioxygenase, which disrupts the normal degradation of tyrosine. This ...
BOSTON, July 17, 2025--(BUSINESS WIRE)--Cycle Pharmaceuticals announced the launch of HARLIKU, the first and only FDA-approved treatment for reducing urinary homogentisic acid (HGA) in adult patients ...
Alkaptonuria is caused by the deficiency of a single enzyme called homogentisate 1,2 dioxygenase. This is responsible for the degradation of homogentisic acid (HGA) to maleylacetoacetic acid via the ...
Alkaptonuria, caused by mutations in the HGO gene and a deficiency of homogentisate 1,2-dioxygenase, results in an accumulation of homogentisic acid (HGA), ochronosis, and destruction of connective ...
This picture of a patient who had alkaptonuria (Fig. 1) was taken by my father, Dr. Ian Maxwell, in 1957 and was developed using the patient's own urine. Alkaptonuria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results